Back to School: How biopharma can reboot drug development. Access exclusive analysis here
AMLN and partner Eli Lilly (LLY) said exenatide synthetic exendin-4 met the primary endpoint of a reduction in glucose levels
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury